"Molecule ChEMBL ID";"Molecule Name";"Molecule Max Phase";"Molecular Weight";"#RO5 Violations";"AlogP";"Compound Key";"Smiles";"Standard Type";"Standard Relation";"Standard Value";"Standard Units";"pChEMBL Value";"Data Validity Comment";"Comment";"Uo Units";"Ligand Efficiency BEI";"Ligand Efficiency LE";"Ligand Efficiency LLE";"Ligand Efficiency SEI";"Potential Duplicate";"Assay ChEMBL ID";"Assay Description";"Assay Type";"BAO Format ID";"BAO Label";"Assay Organism";"Assay Tissue ChEMBL ID";"Assay Tissue Name";"Assay Cell Type";"Assay Subcellular Fraction";"Assay Parameters";"Assay Variant Accession";"Assay Variant Mutation";"Target ChEMBL ID";"Target Name";"Target Organism";"Target Type";"Document ChEMBL ID";"Source ID";"Source Description";"Document Journal";"Document Year";"Cell ChEMBL ID";"Properties";"Action Type";"Standard Text Value";"Value"
"CHEMBL5606429";"";"None";"378.41";"0";"3.36";"ASAP-0031147";"O=C(Nc1cc2c(c(C3=CCOCC3)c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'='";"8469.0";"nM";"5.07";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.188 None | IC50 CI (lower) = 7.725 uM | IC50 CI (upper) = 9.285 uM | Maximum measured = 97.56 None | Maximum response = 100.0 % | Minimum measured = -5.257 None | R squared = 0.993 None";"";"";"8.469"
"CHEMBL5605908";"";"None";"403.42";"0";"3.63";"ASAP-0031141";"COc1cc(-c2cc(NC(=O)c3cc(F)cc4[nH]ncc34)cc3c2CNC3)ccn1";"IC50";"'='";"12911.0";"nM";"4.89";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.218 None | IC50 CI (lower) = 11.48 uM | IC50 CI (upper) = 14.52 uM | Maximum measured = 90.98 None | Maximum response = 100.0 % | Minimum measured = -6.173 None | R squared = 0.986 None";"";"";"12.911"
"CHEMBL5598743";"";"None";"425.96";"0";"4.27";"ASAP-0029555";"O=C(NC1CCOCC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'='";"53424.0";"nM";"4.27";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.986 None | IC50 CI (lower) = 48.47 uM | IC50 CI (upper) = 58.88 uM | Maximum measured = 64.76 None | Maximum response = 100.0 % | Minimum measured = -3.987 None | R squared = 0.986 None";"";"";"53.424"
"CHEMBL5604849";"";"None";"409.96";"0";"4.89";"ASAP-0030790";"O=C(NCCC1CC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.123 None | Maximum measured = 36.26 None | Maximum response = 100.0 % | Minimum measured = -9.496 None | R squared = 0.831 None";"";"";"99.5"
"CHEMBL5605115";"";"None";"375.20";"0";"3.32";"ASAP-0030792";"O=C(Nc1cc(Br)c2c(c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'='";"14995.0";"nM";"4.82";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.697 None | IC50 CI (lower) = 11.37 uM | IC50 CI (upper) = 19.78 uM | Maximum measured = 73.06 None | Maximum response = 100.0 % | Minimum measured = -3.109 None | R squared = 0.938 None";"";"";"14.995"
"CHEMBL5605716";"";"None";"305.34";"0";"2.80";"ASAP-0029967";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2nc(O)ccc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.159 None | Maximum measured = 41.64 None | Maximum response = 100.0 % | Minimum measured = 0.86 None | R squared = 0.977 None";"";"";"99.5"
"CHEMBL3919119";"";"None";"454.34";"None";"None";"ASAP-0015081";"N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)c1ccccc1)B(O)O";"IC50";"'='";"784.0";"nM";"6.11";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.088 None | IC50 CI (lower) = 0.743 uM | IC50 CI (upper) = 0.828 uM | Maximum measured = 99.42 None | Maximum response = 100.0 % | Minimum measured = 4.646 None | R squared = 0.997 None";"";"";"0.784"
"CHEMBL5606153";"";"None";"423.90";"1";"5.11";"ASAP-0021119";"Cc1ccc(NC(=O)c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)cc1CN";"IC50";"'='";"57739.0";"nM";"4.24";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.639 None | IC50 CI (lower) = 54.78 uM | IC50 CI (upper) = 60.86 uM | Maximum measured = 78.63 None | Maximum response = 100.0 % | Minimum measured = -3.275 None | R squared = 0.987 None";"";"";"57.739"
"CHEMBL5605664";"";"None";"390.39";"0";"4.36";"ASAP-0031237";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccc(F)cc3)nc12";"IC50";"'='";"2955.0";"nM";"5.53";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.454 None | IC50 CI (lower) = 2.475 uM | IC50 CI (upper) = 3.527 uM | Maximum measured = 95.63 None | Maximum response = 100.0 % | Minimum measured = -4.923 None | R squared = 0.967 None";"";"";"2.955"
"CHEMBL5605985";"";"None";"416.48";"0";"2.84";"ASAP-0031120";"CC(C)(c1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(F)cc2[nH]1)S(C)(=O)=O";"IC50";"'='";"13646.0";"nM";"4.87";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.763 None | IC50 CI (lower) = 12.45 uM | IC50 CI (upper) = 14.96 uM | Maximum measured = 95.84 None | Maximum response = 100.0 % | Minimum measured = -8.152 None | R squared = 0.985 None";"";"";"13.646"
"CHEMBL5605103";"";"None";"386.43";"0";"4.53";"ASAP-0031310";"Cc1ccccc1-c1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(F)cc2[nH]1";"IC50";"'='";"2196.0";"nM";"5.66";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.93 None | IC50 CI (lower) = 1.975 uM | IC50 CI (upper) = 2.442 uM | Maximum measured = 96.89 None | Maximum response = 100.0 % | Minimum measured = 1.778 None | R squared = 0.987 None";"";"";"2.196"
"CHEMBL5605310";"";"None";"399.52";"0";"4.88";"ASAP-0031492";"NCc1ccc(-c2csc3cc(C(=O)Nc4ccc5c(c4)CNC5)ccc23)cc1";"IC50";"'='";"31579.0";"nM";"4.50";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.389 None | IC50 CI (lower) = 30.01 uM | IC50 CI (upper) = 33.23 uM | Maximum measured = 81.14 None | Maximum response = 100.0 % | Minimum measured = -0.973 None | R squared = 0.995 None";"";"";"31.579"
"CHEMBL5604470";"";"None";"397.41";"0";"4.10";"ASAP-0031299";"N#Cc1ccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)cc1";"IC50";"'='";"1704.0";"nM";"5.77";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.776 None | IC50 CI (lower) = 1.595 uM | IC50 CI (upper) = 1.82 uM | Maximum measured = 95.99 None | Maximum response = 100.0 % | Minimum measured = 1.64 None | R squared = 0.995 None";"";"";"1.704"
"CHEMBL5598749";"";"None";"421.88";"0";"4.94";"ASAP-0020915";"O=C(Nc1cc(Cl)cc(C(=O)Nc2ccc3c(c2)CNC3)c1)OCc1ccccc1";"IC50";"'='";"72465.0";"nM";"4.14";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.585 None | IC50 CI (lower) = 66.12 uM | IC50 CI (upper) = 79.41 uM | Maximum measured = 60.5 None | Maximum response = 100.0 % | Minimum measured = -5.998 None | R squared = 0.974 None";"";"";"72.465"
"CHEMBL5605856";"";"None";"406.91";"1";"5.82";"ASAP-0027760";"NCc1ccc([C@H]2C[C@@H]2c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)cc1";"IC50";"'='";"6849.0";"nM";"5.16";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 6.53 None | IC50 CI (lower) = 6.15 uM | IC50 CI (upper) = 7.628 uM | Maximum measured = 99.45 None | Maximum response = 100.0 % | Minimum measured = -10.24 None | R squared = 0.991 None";"";"";"6.849"
"CHEMBL5605186";"";"None";"461.01";"1";"6.83";"ASAP-0027756";"O=C(Nc1cc(Cl)cc([C@H]2C[C@@H]2c2cccc(C3CCNCC3)c2)c1)OCc1ccccc1";"IC50";"'='";"4789.0";"nM";"5.32";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.893 None | IC50 CI (lower) = 4.03 uM | IC50 CI (upper) = 5.69 uM | Maximum measured = 99.83 None | Maximum response = 100.0 % | Minimum measured = -12.24 None | R squared = 0.98 None";"";"";"4.789"
"CHEMBL5605468";"";"None";"295.32";"0";"3.16";"ASAP-0029832";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)c2[nH]ccc2c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.715 None | Maximum measured = 27.79 None | Maximum response = 100.0 % | Minimum measured = -1.599 None | R squared = 0.957 None";"";"";"99.5"
"CHEMBL5598746";"";"None";"435.96";"0";"4.02";"ASAP-0029471";"Cn1cc(CNC(=O)[C@H](Nc2ccc3c(c2)CNC3)c2cc(Cl)cc(C3CC3)c2)cn1";"IC50";"'='";"81762.0";"nM";"4.09";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.054 None | IC50 CI (lower) = 76.23 uM | IC50 CI (upper) = 87.7 uM | Maximum measured = 55.58 None | Maximum response = 100.0 % | Minimum measured = -2.197 None | R squared = 0.991 None";"";"";"81.762"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"2225.0";"nM";"5.65";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.152 None | IC50 CI (lower) = 2.135 uM | IC50 CI (upper) = 2.319 uM | Maximum measured = 99.55 None | Maximum response = 100.0 % | Minimum measured = -1.913 None | R squared = 0.999 None";"";"";"2.225"
"CHEMBL5598605";"";"None";"305.34";"0";"3.20";"ASAP-0029713";"O=C(Nc1ccc2c(c1)CNC2)c1cccc(-c2cnco2)c1";"IC50";"'='";"21244.0";"nM";"4.67";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.278 None | IC50 CI (lower) = 20.11 uM | IC50 CI (upper) = 22.44 uM | Maximum measured = 94.34 None | Maximum response = 100.0 % | Minimum measured = -1.923 None | R squared = 0.994 None";"";"";"21.244"
"CHEMBL5598786";"";"None";"296.30";"0";"2.56";"ASAP-0029497";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'='";"23396.0";"nM";"4.63";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.939 None | IC50 CI (lower) = 20.97 uM | IC50 CI (upper) = 26.1 uM | Maximum measured = 73.66 None | Maximum response = 100.0 % | Minimum measured = -2.817 None | R squared = 0.986 None";"";"";"23.396"
"CHEMBL5604332";"";"None";"312.76";"0";"3.07";"ASAP-0027808";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'='";"13371.0";"nM";"4.87";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.962 None | IC50 CI (lower) = 11.71 uM | IC50 CI (upper) = 15.26 uM | Maximum measured = 87.07 None | Maximum response = 100.0 % | Minimum measured = -0.359 None | R squared = 0.983 None";"";"";"13.371"
"CHEMBL5598717";"";"None";"565.08";"2";"6.65";"ASAP-0027928";"O=C(Nc1cc(Cl)cc([C@H]2CN(Cc3ccccc3)C[C@@H]2c2cccc(-c3nn[nH]n3)c2)c1)OCc1ccccc1";"IC50";"'='";"6031.0";"nM";"5.22";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.734 None | IC50 CI (lower) = 5.554 uM | IC50 CI (upper) = 6.55 uM | Maximum measured = 97.19 None | Maximum response = 100.0 % | Minimum measured = -3.722 None | R squared = 0.994 None";"";"";"6.031"
"CHEMBL5598593";"";"None";"309.76";"0";"3.59";"ASAP-0027972";"Clc1ccc2[nH]cc(Cc3ccc(-c4nn[nH]n4)cc3)c2c1";"IC50";"'='";"44119.0";"nM";"4.36";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.92 None | IC50 CI (lower) = 42.21 uM | IC50 CI (upper) = 46.11 uM | Maximum measured = 93.49 None | Maximum response = 100.0 % | Minimum measured = -1.96 None | R squared = 0.993 None";"";"";"44.119"
"CHEMBL5605497";"";"None";"463.97";"1";"5.94";"ASAP-0023377";"N[C@H]1CC[C@H](c2ccc(NC(=O)c3cc(Cl)cc(NC(=O)OCc4ccccc4)c3)cc2)C1";"IC50";"'='";"5841.0";"nM";"5.23";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 4.389 None | IC50 CI (lower) = 4.629 uM | IC50 CI (upper) = 7.37 uM | Maximum measured = 100.0 None | Maximum response = 100.0 % | Minimum measured = -9.128 None | R squared = 0.979 None";"";"";"5.841"
"CHEMBL5605947";"";"None";"435.91";"0";"4.99";"ASAP-0027652";"O=C(Nc1cc(Cl)cc(C(=O)Nc2ccc3c(c2)CCNC3)c1)OCc1ccccc1";"IC50";"'='";"24351.0";"nM";"4.61";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 4.318 None | IC50 CI (lower) = 21.98 uM | IC50 CI (upper) = 26.98 uM | Maximum measured = 96.92 None | Maximum response = 100.0 % | Minimum measured = -11.74 None | R squared = 0.961 None";"";"";"24.351"
"CHEMBL5598591";"";"None";"373.29";"0";"4.60";"ASAP-0029041";"CC(C)(C)c1cc(Br)cc(C(=O)Nc2ccc3c(c2)CNC3)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = -1.082 None | Minimum measured = -12.29 None";"";"";"99.5"
"CHEMBL5598597";"";"None";"326.79";"0";"3.41";"ASAP-0029027";"CN1Cc2ccc(NC(=O)c3cc(Cl)cc4[nH]ncc34)cc2C1";"IC50";"'='";"92766.0";"nM";"4.03";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.806 None | IC50 CI (lower) = 77.52 uM | IC50 CI (upper) = 111.0 uM | Maximum measured = 48.45 None | Maximum response = 100.0 % | Minimum measured = -3.071 None | R squared = 0.97 None";"";"";"92.766"
"CHEMBL5605540";"";"None";"452.94";"0";"4.45";"ASAP-0027609";"CNC(=O)[C@H](Nc1cccc(CN)c1)c1cc(Cl)cc(NC(=O)OCc2ccccc2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.765 None | Maximum measured = 47.69 None | Maximum response = 100.0 % | Minimum measured = -3.899 None | R squared = 0.972 None";"";"";"99.5"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"2186.0";"nM";"5.66";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.161 None | IC50 CI (lower) = 2.114 uM | IC50 CI (upper) = 2.26 uM | Maximum measured = 99.1 None | Maximum response = 100.0 % | Minimum measured = -0.92 None | R squared = 0.999 None";"";"";"2.186"
"CHEMBL5598577";"";"None";"326.79";"0";"3.11";"ASAP-0029079";"O=C(Nc1ccc2c(c1)CNCC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'='";"93850.0";"nM";"4.03";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.131 None | IC50 CI (lower) = 85.18 uM | IC50 CI (upper) = 103.41 uM | Maximum measured = 50.73 None | Maximum response = 100.0 % | Minimum measured = -2.971 None | R squared = 0.984 None";"";"";"93.85"
"CHEMBL5604695";"";"None";"352.83";"0";"4.19";"ASAP-0029944";"C=CC[C@H]1NCc2cc(NC(=O)c3cc(Cl)cc4[nH]ncc34)ccc21";"IC50";"'='";"68208.0";"nM";"4.17";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.068 None | IC50 CI (lower) = 62.59 uM | IC50 CI (upper) = 74.33 uM | Maximum measured = 58.59 None | Maximum response = 100.0 % | Minimum measured = -1.847 None | R squared = 0.987 None";"";"";"68.208"
"CHEMBL5605097";"";"None";"386.43";"0";"4.53";"ASAP-0031293";"Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1";"IC50";"'='";"6161.0";"nM";"5.21";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.828 None | IC50 CI (lower) = 5.523 uM | IC50 CI (upper) = 6.874 uM | Maximum measured = 81.98 None | Maximum response = 100.0 % | Minimum measured = -2.382 None | R squared = 0.984 None";"";"";"6.161"
"CHEMBL5604806";"";"None";"420.85";"1";"5.94";"ASAP-0027839";"O=C(Nc1cc(Cl)cc(-c2ccc3[nH]c(C(=O)O)cc3c2)c1)OCc1ccccc1";"IC50";"'='";"4997.0";"nM";"5.30";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.984 None | IC50 CI (lower) = 4.673 uM | IC50 CI (upper) = 5.343 uM | Maximum measured = 100.14 None | Maximum response = 100.0 % | Minimum measured = -3.109 None | R squared = 0.997 None";"";"";"4.997"
"CHEMBL5606112";"";"None";"337.45";"0";"3.26";"ASAP-0031277";"NCCc1csc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.432 None | Maximum measured = 47.5 None | Maximum response = 100.0 % | Minimum measured = -7.186 None | R squared = 0.91 None";"";"";"99.5"
"CHEMBL5604989";"";"None";"390.39";"0";"4.36";"ASAP-0031443";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3cccc(F)c3)nc12";"IC50";"'='";"2730.0";"nM";"5.56";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.377 None | IC50 CI (lower) = 2.493 uM | IC50 CI (upper) = 2.99 uM | Maximum measured = 96.67 None | Maximum response = 100.0 % | Minimum measured = -0.417 None | R squared = 0.991 None";"";"";"2.73"
"CHEMBL5605526";"";"None";"409.87";"0";"4.80";"ASAP-0016806";"NCc1cccc(NC(=O)c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)c1";"IC50";"'='";"26759.0";"nM";"4.57";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.378 None | IC50 CI (lower) = 25.0 uM | IC50 CI (upper) = 28.64 uM | Maximum measured = 94.8 None | Maximum response = 100.0 % | Minimum measured = -7.136 None | R squared = 0.987 None";"";"";"26.759"
"CHEMBL5605162";"";"None";"387.87";"0";"3.27";"ASAP-0028981";"CNC(=O)[C@H](Nc1cc(CN)cc(C(=O)O)c1)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.401 None | Maximum measured = 10.37 None | Maximum response = 100.0 % | Minimum measured = -2.48 None | R squared = 0.696 None";"";"";"99.5"
"CHEMBL5604344";"";"None";"373.21";"0";"2.47";"ASAP-0029916";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]c(=O)[nH]c12";"IC50";"'='";"21547.0";"nM";"4.67";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.907 None | IC50 CI (lower) = 19.34 uM | IC50 CI (upper) = 24.0 uM | Maximum measured = 74.88 None | Maximum response = 100.0 % | Minimum measured = -2.38 None | R squared = 0.987 None";"";"";"21.547"
"CHEMBL5604703";"";"None";"326.79";"0";"3.38";"ASAP-0029875";"Cc1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(Cl)cc2[nH]1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.5 None | Maximum measured = 41.16 None | Maximum response = 100.0 % | Minimum measured = -7.653 None | R squared = 0.142 None";"";"";"99.5"
"CHEMBL5604471";"";"None";"332.41";"0";"3.92";"ASAP-0029790";"Cc1c(C(=O)Nc2cc(-c3cccnc3)ccn2)cc(C2CC2)n1C";"IC50";"'='";"6221.0";"nM";"5.21";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 4.205 None | IC50 CI (lower) = 5.652 uM | IC50 CI (upper) = 6.848 uM | Maximum measured = 98.68 None | Maximum response = 100.0 % | Minimum measured = -2.546 None | R squared = 0.994 None";"";"";"6.221"
"CHEMBL5598718";"";"None";"298.78";"0";"3.43";"ASAP-0029525";"Clc1cc(CNc2ccc3c(c2)CNC3)c2cn[nH]c2c1";"IC50";"'='";"42234.0";"nM";"4.37";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.691 None | IC50 CI (lower) = 37.38 uM | IC50 CI (upper) = 47.71 uM | Maximum measured = 79.3 None | Maximum response = 100.0 % | Minimum measured = -9.561 None | R squared = 0.95 None";"";"";"42.234"
"CHEMBL5598576";"";"None";"405.88";"0";"4.36";"ASAP-0029491";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'='";"28457.0";"nM";"4.55";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.986 None | IC50 CI (lower) = 26.14 uM | IC50 CI (upper) = 30.98 uM | Maximum measured = 77.08 None | Maximum response = 100.0 % | Minimum measured = -4.221 None | R squared = 0.991 None";"";"";"28.457"
"CHEMBL5604249";"";"None";"406.91";"1";"5.82";"ASAP-0022797";"NCc1cccc([C@H]2C[C@@H]2c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)c1";"IC50";"'='";"7852.0";"nM";"5.11";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.451 None | IC50 CI (lower) = 7.172 uM | IC50 CI (upper) = 8.596 uM | Maximum measured = 94.34 None | Maximum response = 100.0 % | Minimum measured = -8.578 None | R squared = 0.984 None";"";"";"7.852"
"CHEMBL3919119";"";"None";"454.34";"None";"None";"ASAP-0015081";"N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)c1ccccc1)B(O)O";"IC50";"'='";"980.0";"nM";"6.01";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.138 None | IC50 CI (lower) = 0.931 uM | IC50 CI (upper) = 1.031 uM | Maximum measured = 99.34 None | Maximum response = 100.0 % | Minimum measured = 3.134 None | R squared = 0.998 None";"";"";"0.98"
"CHEMBL5605142";"";"None";"474.95";"1";"6.00";"ASAP-0028884";"C=CC[C@H](Nc1cc(Cl)cc(NC(=O)OCc2ccccc2)c1)c1cccc(-c2nn[nH]n2)c1";"IC50";"'='";"6430.0";"nM";"5.19";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.013 None | IC50 CI (lower) = 6.018 uM | IC50 CI (upper) = 6.87 uM | Maximum measured = 100.81 None | Maximum response = 100.0 % | Minimum measured = -3.131 None | R squared = 0.996 None";"";"";"6.43"
"CHEMBL5605069";"";"None";"311.77";"0";"3.68";"ASAP-0030001";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2cc[nH]c12";"IC50";"'='";"87872.0";"nM";"4.06";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.217 None | IC50 CI (lower) = 79.88 uM | IC50 CI (upper) = 96.67 uM | Maximum measured = 53.8 None | Maximum response = 100.0 % | Minimum measured = -1.642 None | R squared = 0.98 None";"";"";"87.872"
"CHEMBL5604539";"";"None";"388.39";"0";"3.44";"ASAP-0030867";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ccc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 10.13 None | Maximum measured = 10.25 None | Maximum response = 100.0 % | Minimum measured = -6.706 None | R squared = 0.033 None";"";"";"99.5"
"CHEMBL5605366";"";"None";"425.92";"0";"3.27";"ASAP-0029888";"O=C(NC1CCOCC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'='";"39513.0";"nM";"4.40";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.0 None | IC50 CI (lower) = 36.57 uM | IC50 CI (upper) = 42.7 uM | Maximum measured = 69.88 None | Maximum response = 100.0 % | Minimum measured = -2.144 None | R squared = 0.991 None";"";"";"39.513"
"CHEMBL5605549";"";"None";"294.31";"0";"1.71";"ASAP-0029783";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2[nH]c(=O)[nH]c12";"IC50";"'='";"40810.0";"nM";"4.39";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.998 None | IC50 CI (lower) = 38.59 uM | IC50 CI (upper) = 43.16 uM | Maximum measured = 71.33 None | Maximum response = 100.0 % | Minimum measured = -0.067 None | R squared = 0.995 None";"";"";"40.81"
"CHEMBL5605238";"";"None";"375.50";"0";"4.13";"ASAP-0031464";"O=C(Nc1ccc2c(c1)CNC2)c1ccc2c(C3=CCNCC3)csc2c1";"IC50";"'='";"54442.0";"nM";"4.26";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.049 None | IC50 CI (lower) = 51.41 uM | IC50 CI (upper) = 57.66 uM | Maximum measured = 79.45 None | Maximum response = 100.0 % | Minimum measured = -1.904 None | R squared = 0.988 None";"";"";"54.442"
"CHEMBL5599838";"";"None";"459.98";"1";"5.16";"ASAP-0031456";"CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]c(-c3ccccc3)nc12";"IC50";"'='";"2207.0";"nM";"5.66";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.943 None | IC50 CI (lower) = 2.088 uM | IC50 CI (upper) = 2.332 uM | Maximum measured = 96.45 None | Maximum response = 100.0 % | Minimum measured = 4.502 None | R squared = 0.998 None";"";"";"2.207"
"CHEMBL5604531";"";"None";"402.43";"0";"4.23";"ASAP-0031290";"COc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1";"IC50";"'='";"3719.0";"nM";"5.43";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.365 None | IC50 CI (lower) = 3.11 uM | IC50 CI (upper) = 4.448 uM | Maximum measured = 92.0 None | Maximum response = 100.0 % | Minimum measured = 0.699 None | R squared = 0.971 None";"";"";"3.719"
"CHEMBL5606266";"";"None";"277.33";"0";"3.02";"ASAP-0029756";"O=C(Nc1ccc2c(c1)CNC2)c1ccc2[nH]ccc2c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.911 None | Maximum measured = 23.95 None | Maximum response = 100.0 % | Minimum measured = -4.722 None | R squared = 0.727 None";"";"";"99.5"
"CHEMBL5604118";"";"None";"367.47";"0";"3.55";"ASAP-0031158";"NCCc1csc2cc(C(=O)Nc3cc([C@H]4CCOC4)ccn3)ccc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 0.149 None | Minimum measured = -8.911 None";"";"";"99.5"
"CHEMBL5605520";"";"None";"352.82";"0";"2.97";"ASAP-0028990";"OCC#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'='";"26215.0";"nM";"4.58";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 4.483 None | IC50 CI (lower) = 24.61 uM | IC50 CI (upper) = 27.93 uM | Maximum measured = 95.32 None | Maximum response = 100.0 % | Minimum measured = -10.25 None | R squared = 0.984 None";"";"";"26.215"
"CHEMBL5605533";"";"None";"418.88";"0";"4.75";"ASAP-0029841";"Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(Cl)cc3[nH]2)c1O";"IC50";"'='";"4441.0";"nM";"5.35";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.715 None | IC50 CI (lower) = 3.683 uM | IC50 CI (upper) = 5.354 uM | Maximum measured = 96.26 None | Maximum response = 100.0 % | Minimum measured = -10.12 None | R squared = 0.979 None";"";"";"4.441"
"CHEMBL5598575";"";"None";"399.92";"0";"3.74";"ASAP-0029415";"COCCNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'='";"63358.0";"nM";"4.20";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.053 None | IC50 CI (lower) = 57.21 uM | IC50 CI (upper) = 70.17 uM | Maximum measured = 63.66 None | Maximum response = 100.0 % | Minimum measured = -0.752 None | R squared = 0.982 None";"";"";"63.358"
"CHEMBL5605910";"";"None";"413.91";"0";"3.13";"ASAP-0029914";"CCOCCNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.166 None | Maximum measured = 37.99 None | Maximum response = 100.0 % | Minimum measured = -0.481 None | R squared = 0.98 None";"";"";"99.5"
"CHEMBL5604180";"";"None";"312.76";"0";"3.07";"ASAP-0029911";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2cn[nH]c12";"IC50";"'='";"41870.0";"nM";"4.38";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.045 None | IC50 CI (lower) = 39.62 uM | IC50 CI (upper) = 44.25 uM | Maximum measured = 71.26 None | Maximum response = 100.0 % | Minimum measured = -1.292 None | R squared = 0.995 None";"";"";"41.87"
"CHEMBL5598927";"";"None";"372.22";"0";"2.80";"ASAP-0029728";"O=C1Cc2c(cc(Br)cc2C(=O)Nc2ccc3c(c2)CNC3)N1";"IC50";"'='";"17849.0";"nM";"4.75";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.045 None | IC50 CI (lower) = 17.0 uM | IC50 CI (upper) = 18.74 uM | Maximum measured = 86.97 None | Maximum response = 100.0 % | Minimum measured = 0.357 None | R squared = 0.997 None";"";"";"17.849"
"CHEMBL5598576";"";"None";"405.88";"0";"4.36";"ASAP-0030776";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'='";"23817.0";"nM";"4.62";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.094 None | IC50 CI (lower) = 21.71 uM | IC50 CI (upper) = 26.13 uM | Maximum measured = 81.1 None | Maximum response = 100.0 % | Minimum measured = -3.933 None | R squared = 0.989 None";"";"";"23.817"
"CHEMBL5606160";"";"None";"372.40";"0";"4.22";"ASAP-0030089";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccccc3)nc12";"IC50";"'='";"3568.0";"nM";"5.45";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.439 None | IC50 CI (lower) = 2.905 uM | IC50 CI (upper) = 4.382 uM | Maximum measured = 92.07 None | Maximum response = 100.0 % | Minimum measured = -2.255 None | R squared = 0.959 None";"";"";"3.568"
"CHEMBL5598610";"";"None";"383.88";"0";"3.50";"ASAP-0029974";"CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'='";"26162.0";"nM";"4.58";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.199 None | IC50 CI (lower) = 24.02 uM | IC50 CI (upper) = 28.49 uM | Maximum measured = 87.81 None | Maximum response = 100.0 % | Minimum measured = -3.276 None | R squared = 0.99 None";"";"";"26.162"
"CHEMBL5604216";"";"None";"397.41";"0";"4.10";"ASAP-0031247";"N#Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1";"IC50";"'='";"2307.0";"nM";"5.64";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.192 None | IC50 CI (lower) = 1.966 uM | IC50 CI (upper) = 2.707 uM | Maximum measured = 94.36 None | Maximum response = 100.0 % | Minimum measured = -5.715 None | R squared = 0.968 None";"";"";"2.307"
"CHEMBL5604988";"";"None";"399.52";"0";"4.88";"ASAP-0031461";"NCc1cccc(-c2csc3cc(C(=O)Nc4ccc5c(c4)CNC5)ccc23)c1";"IC50";"'='";"29787.0";"nM";"4.53";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.832 None | IC50 CI (lower) = 28.13 uM | IC50 CI (upper) = 31.54 uM | Maximum measured = 94.14 None | Maximum response = 100.0 % | Minimum measured = -1.579 None | R squared = 0.993 None";"";"";"29.787"
"CHEMBL5604667";"";"None";"422.49";"0";"4.20";"ASAP-0031355";"CC(C)c1nnc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)s1";"IC50";"'='";"10818.0";"nM";"4.97";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.449 None | IC50 CI (lower) = 9.076 uM | IC50 CI (upper) = 12.89 uM | Maximum measured = 81.16 None | Maximum response = 100.0 % | Minimum measured = -0.345 None | R squared = 0.962 None";"";"";"10.818"
"CHEMBL5605561";"";"None";"333.40";"0";"2.11";"ASAP-0031692";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2c(C3CNC3)n[nH]c12";"IC50";"'='";"9270.0";"nM";"5.03";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.955 None | IC50 CI (lower) = 8.971 uM | IC50 CI (upper) = 9.579 uM | Maximum measured = 90.35 None | Maximum response = 100.0 % | Minimum measured = 0.978 None | R squared = 0.999 None";"";"";"9.27"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"1495.0";"nM";"5.83";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.091 None | IC50 CI (lower) = 1.442 uM | IC50 CI (upper) = 1.551 uM | Maximum measured = 99.53 None | Maximum response = 100.0 % | Minimum measured = 0.208 None | R squared = 0.999 None";"";"";"1.495"
"CHEMBL5605251";"";"None";"493.41";"1";"5.97";"ASAP-0015849";"CC(C)CNC(=O)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Oc2ccccc2Cl)cc1";"IC50";"'='";"12111.0";"nM";"4.92";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.284 None | IC50 CI (lower) = 9.895 uM | IC50 CI (upper) = 14.82 uM | Maximum measured = 79.48 None | Maximum response = 100.0 % | Minimum measured = -1.644 None | R squared = 0.953 None";"";"";"12.111"
"CHEMBL5606202";"";"None";"344.46";"0";"4.73";"ASAP-0021052";"Cc1[nH]c2ccccc2c1CN1CCC(c2c[nH]c3ncccc23)CC1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.927 None | Maximum measured = 11.12 None | Maximum response = 100.0 % | Minimum measured = -2.78 None | R squared = 0.773 None";"";"";"99.5"
"CHEMBL5598898";"";"None";"323.78";"0";"3.74";"ASAP-0029711";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2ccncc12";"IC50";"'='";"69764.0";"nM";"4.16";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.189 None | IC50 CI (lower) = 63.25 uM | IC50 CI (upper) = 76.95 uM | Maximum measured = 60.5 None | Maximum response = 100.0 % | Minimum measured = -3.488 None | R squared = 0.981 None";"";"";"69.764"
"CHEMBL5598685";"";"None";"323.83";"0";"4.50";"ASAP-0029597";"N#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 1.006 None | Minimum measured = -33.06 None";"";"";"99.5"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"2219.0";"nM";"5.65";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.149 None | IC50 CI (lower) = 2.146 uM | IC50 CI (upper) = 2.296 uM | Maximum measured = 98.93 None | Maximum response = 100.0 % | Minimum measured = -1.075 None | R squared = 0.999 None";"";"";"2.219"
"CHEMBL5598658";"";"None";"355.87";"0";"3.72";"ASAP-0029621";"CNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.765 None | Maximum measured = 13.78 None | Maximum response = 100.0 % | Minimum measured = -2.347 None | R squared = 0.857 None";"";"";"99.5"
"CHEMBL5605274";"";"None";"390.39";"0";"4.36";"ASAP-0031221";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccccc3F)nc12";"IC50";"'='";"3444.0";"nM";"5.46";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.184 None | IC50 CI (lower) = 2.864 uM | IC50 CI (upper) = 4.141 uM | Maximum measured = 95.66 None | Maximum response = 100.0 % | Minimum measured = -5.563 None | R squared = 0.969 None";"";"";"3.444"
"CHEMBL5604418";"";"None";"351.88";"0";"4.95";"ASAP-0029785";"Clc1cc([C@@H]2C[C@H]2c2cccc(C3CCNCC3)c2)c2cn[nH]c2c1";"IC50";"'='";"6448.0";"nM";"5.19";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 17.92 None | IC50 CI (lower) = 0.0 uM | IC50 CI (upper) = -7982982183235092000 uM | Maximum measured = 100.69 None | Maximum response = 100.0 % | Minimum measured = -10.02 None | R squared = 0.992 None";"";"";"6.448"
"CHEMBL5605521";"";"None";"296.35";"0";"3.17";"ASAP-0030106";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2c1CCC2";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.485 None | Maximum measured = 22.5 None | Maximum response = 100.0 % | Minimum measured = -1.162 None | R squared = 0.927 None";"";"";"99.5"
"CHEMBL5604164";"";"None";"345.32";"0";"4.04";"ASAP-0030028";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2[nH]c(C(F)(F)F)cc12";"IC50";"'='";"31764.0";"nM";"4.50";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.993 None | IC50 CI (lower) = 29.72 uM | IC50 CI (upper) = 33.95 uM | Maximum measured = 74.3 None | Maximum response = 100.0 % | Minimum measured = -1.539 None | R squared = 0.994 None";"";"";"31.764"
"CHEMBL5606201";"";"None";"389.85";"0";"3.93";"ASAP-0030082";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2nn(-c3ccccc3)nc12";"IC50";"'='";"4726.0";"nM";"5.33";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.628 None | IC50 CI (lower) = 4.021 uM | IC50 CI (upper) = 5.554 uM | Maximum measured = 96.52 None | Maximum response = 100.0 % | Minimum measured = -9.582 None | R squared = 0.985 None";"";"";"4.726"
"CHEMBL5606236";"";"None";"375.20";"0";"3.32";"ASAP-0030085";"O=C(Nc1cc2c(cc1Br)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'='";"21759.0";"nM";"4.66";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.001 None | IC50 CI (lower) = 20.15 uM | IC50 CI (upper) = 23.49 uM | Maximum measured = 81.81 None | Maximum response = 100.0 % | Minimum measured = -4.603 None | R squared = 0.993 None";"";"";"21.759"
"CHEMBL5604338";"";"None";"360.46";"0";"3.49";"ASAP-0031404";"O=C(Nc1ccc2c(c1)CNC2)c1ccc2[nH]cc(C3CCNCC3)c2c1";"IC50";"'='";"29240.0";"nM";"4.53";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.88 None | IC50 CI (lower) = 27.94 uM | IC50 CI (upper) = 30.6 uM | Maximum measured = 97.59 None | Maximum response = 100.0 % | Minimum measured = -1.371 None | R squared = 0.993 None";"";"";"29.24"
"CHEMBL5599838";"";"None";"459.98";"1";"5.16";"ASAP-0030826";"CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]c(-c3ccccc3)nc12";"IC50";"'='";"7062.0";"nM";"5.15";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.029 None | IC50 CI (lower) = 6.595 uM | IC50 CI (upper) = 7.563 uM | Maximum measured = 93.63 None | Maximum response = 100.0 % | Minimum measured = -3.544 None | R squared = 0.996 None";"";"";"7.062"
"CHEMBL5606033";"";"None";"293.33";"0";"2.04";"ASAP-0029950";"O=C1Cc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc2N1";"IC50";"'='";"7129.0";"nM";"5.15";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.411 None | IC50 CI (lower) = 6.665 uM | IC50 CI (upper) = 7.624 uM | Maximum measured = 99.22 None | Maximum response = 100.0 % | Minimum measured = -4.225 None | R squared = 0.993 None";"";"";"7.129"
"CHEMBL5598845";"";"None";"356.22";"0";"3.79";"ASAP-0029002";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]ccc12";"IC50";"'='";"44599.0";"nM";"4.35";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.104 None | IC50 CI (lower) = 42.59 uM | IC50 CI (upper) = 46.71 uM | Maximum measured = 86.45 None | Maximum response = 100.0 % | Minimum measured = -2.531 None | R squared = 0.991 None";"";"";"44.599"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"2447.0";"nM";"5.61";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.189 None | IC50 CI (lower) = 2.282 uM | IC50 CI (upper) = 2.623 uM | Maximum measured = 99.69 None | Maximum response = 100.0 % | Minimum measured = -3.752 None | R squared = 0.996 None";"";"";"2.447"
"CHEMBL5605184";"";"None";"311.32";"0";"2.18";"ASAP-0030065";"O=C1Cc2c(cc(F)cc2C(=O)Nc2ccc3c(c2)CNC3)N1";"IC50";"'='";"8591.0";"nM";"5.07";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.08 None | IC50 CI (lower) = 8.022 uM | IC50 CI (upper) = 9.199 uM | Maximum measured = 95.55 None | Maximum response = 100.0 % | Minimum measured = -2.791 None | R squared = 0.996 None";"";"";"8.591"
"CHEMBL5604326";"";"None";"333.39";"0";"3.15";"ASAP-0030062";"C=CC[C@H]1NCc2cc(NC(=O)c3cccc4c3CC(=O)N4)ccc21";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.061 None | Maximum measured = 32.96 None | Maximum response = 100.0 % | Minimum measured = -1.718 None | R squared = 0.953 None";"";"";"99.5"
"CHEMBL5598679";"";"None";"293.33";"0";"2.04";"ASAP-0029208";"O=C1Cc2c(cccc2C(=O)Nc2ccc3c(c2)CNC3)N1";"IC50";"'='";"14233.0";"nM";"4.85";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.893 None | IC50 CI (lower) = 13.53 uM | IC50 CI (upper) = 14.97 uM | Maximum measured = 98.88 None | Maximum response = 100.0 % | Minimum measured = -3.437 None | R squared = 0.995 None";"";"";"14.233"
"CHEMBL5598615";"";"None";"367.25";"0";"4.46";"ASAP-0029045";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2ccccc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.83 None | Maximum measured = 48.76 None | Maximum response = 100.0 % | Minimum measured = -3.569 None | R squared = 0.964 None";"";"";"99.5"
"CHEMBL5605691";"";"None";"312.42";"0";"2.75";"ASAP-0027597";"Cc1c(C(=O)Nc2cc(CCCN)ccn2)cc(C2CC2)n1C";"IC50";"'='";"34474.0";"nM";"4.46";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.512 None | IC50 CI (lower) = 31.32 uM | IC50 CI (upper) = 37.94 uM | Maximum measured = 92.99 None | Maximum response = 100.0 % | Minimum measured = -6.02 None | R squared = 0.977 None";"";"";"34.474"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"2339.0";"nM";"5.63";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.166 None | IC50 CI (lower) = 2.255 uM | IC50 CI (upper) = 2.427 uM | Maximum measured = 98.72 None | Maximum response = 100.0 % | Minimum measured = -0.22 None | R squared = 0.999 None";"";"";"2.339"
"CHEMBL5604114";"";"None";"488.94";"0";"4.42";"ASAP-0027813";"O=C(Nc1cc(Cl)cc([C@H](C#CCO)Nc2cccc(-c3nn[nH]n3)c2)c1)OCc1ccccc1";"IC50";"'='";"11890.0";"nM";"4.92";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.952 None | IC50 CI (lower) = 11.49 uM | IC50 CI (upper) = 12.3 uM | Maximum measured = 98.39 None | Maximum response = 100.0 % | Minimum measured = -1.62 None | R squared = 0.998 None";"";"";"11.89"
"CHEMBL5605532";"";"None";"341.46";"1";"5.10";"ASAP-0016252";"c1cc(C2CCN(Cc3c[nH]c4ccccc34)CC2)c2ccncc2c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.878 None | Maximum measured = 6.464 None | Maximum response = 100.0 % | Minimum measured = -3.076 None | R squared = 0.415 None";"";"";"99.5"
"CHEMBL5604414";"";"None";"464.91";"1";"5.53";"ASAP-0023480";"O=C(Nc1cc(Cl)cc(C(=O)Nc2cccc([C@H]3C[C@H]3C(=O)O)c2)c1)OCc1ccccc1";"IC50";"'='";"22619.0";"nM";"4.65";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.877 None | IC50 CI (lower) = 21.74 uM | IC50 CI (upper) = 23.53 uM | Maximum measured = 96.99 None | Maximum response = 100.0 % | Minimum measured = -3.205 None | R squared = 0.996 None";"";"";"22.619"
"CHEMBL5606457";"";"None";"464.87";"0";"3.61";"ASAP-0023274";"O=C(Nc1cc(Cl)cc(C(=O)Nc2cccc(-n3nn[nH]c3=O)c2)c1)OCc1ccccc1";"IC50";"'='";"10524.0";"nM";"4.98";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.983 None | IC50 CI (lower) = 10.17 uM | IC50 CI (upper) = 10.89 uM | Maximum measured = 97.51 None | Maximum response = 100.0 % | Minimum measured = -2.441 None | R squared = 0.998 None";"";"";"10.524"
"CHEMBL5598576";"";"None";"405.88";"0";"4.36";"ASAP-0030775";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.982 None | Maximum measured = 40.47 None | Maximum response = 100.0 % | Minimum measured = -5.57 None | R squared = 0.951 None";"";"";"99.5"
"CHEMBL5605090";"";"None";"336.37";"0";"3.67";"ASAP-0030071";"C=CC[C@H]1NCc2cc(NC(=O)c3cc(F)cc4[nH]ncc34)ccc21";"IC50";"'='";"32342.0";"nM";"4.49";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.001 None | IC50 CI (lower) = 30.04 uM | IC50 CI (upper) = 34.82 uM | Maximum measured = 74.3 None | Maximum response = 100.0 % | Minimum measured = -3.843 None | R squared = 0.993 None";"";"";"32.342"
"CHEMBL5605639";"";"None";"341.72";"0";"3.61";"ASAP-0029970";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C(F)(F)F)n1";"IC50";"'='";"10399.0";"nM";"4.98";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.252 None | IC50 CI (lower) = 9.674 uM | IC50 CI (upper) = 11.18 uM | Maximum measured = 100.03 None | Maximum response = 100.0 % | Minimum measured = -1.646 None | R squared = 0.992 None";"";"";"10.399"
"CHEMBL5605499";"";"None";"387.24";"0";"2.48";"ASAP-0029933";"Cn1c(=O)[nH]c2c(C(=O)Nc3ccc4c(c3)CNC4)cc(Br)cc21";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 2.244 None | Minimum measured = -27.27 None";"";"";"99.5"
"CHEMBL5598732";"";"None";"359.27";"0";"4.43";"ASAP-0029050";"CC(C)c1cc(Br)cc(C(=O)Nc2ccc3c(c2)CNC3)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = -0.856 None | Minimum measured = -9.918 None";"";"";"99.5"
"CHEMBL5606384";"";"None";"411.90";"0";"2.76";"ASAP-0028903";"CNC(=O)[C@H](Nc1cc(CN)cc(-c2nn[nH]n2)c1)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.367 None | Maximum measured = 19.96 None | Maximum response = 100.0 % | Minimum measured = -2.567 None | R squared = 0.881 None";"";"";"99.5"
"CHEMBL5598631";"";"None";"312.80";"0";"3.68";"ASAP-0029051";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2c1CCC2";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.311 None | Maximum measured = 17.86 None | Maximum response = 100.0 % | Minimum measured = -3.159 None | R squared = 0.879 None";"";"";"99.5"
"CHEMBL5604375";"";"None";"323.79";"0";"3.50";"ASAP-0028904";"N#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.655 None | Maximum measured = 12.55 None | Maximum response = 100.0 % | Minimum measured = -2.133 None | R squared = 0.73 None";"";"";"99.5"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"1634.0";"nM";"5.79";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.181 None | IC50 CI (lower) = 1.547 uM | IC50 CI (upper) = 1.725 uM | Maximum measured = 99.44 None | Maximum response = 100.0 % | Minimum measured = -0.98 None | R squared = 0.998 None";"";"";"1.634"
"CHEMBL3919119";"";"None";"454.34";"None";"None";"ASAP-0015081";"N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)c1ccccc1)B(O)O";"IC50";"'='";"819.0";"nM";"6.09";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.175 None | IC50 CI (lower) = 0.787 uM | IC50 CI (upper) = 0.852 uM | Maximum measured = 99.45 None | Maximum response = 100.0 % | Minimum measured = 1.676 None | R squared = 0.998 None";"";"";"0.819"
"CHEMBL5604328";"";"None";"459.90";"0";"4.95";"ASAP-0027741";"N#C[C@H](Nc1cccc(-c2nn[nH]n2)c1)c1cc(Cl)cc(NC(=O)OCc2ccccc2)c1";"IC50";"'='";"9588.0";"nM";"5.02";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.216 None | IC50 CI (lower) = 9.348 uM | IC50 CI (upper) = 9.835 uM | Maximum measured = 100.88 None | Maximum response = 100.0 % | Minimum measured = -1.376 None | R squared = 0.999 None";"";"";"9.588"
"CHEMBL5605462";"";"None";"491.94";"0";"4.17";"ASAP-0027759";"CNC(=O)[C@H](Nc1cc(Cl)cc(NC(=O)OCc2ccccc2)c1)c1cccc(-c2nn[nH]n2)c1";"IC50";"'='";"40376.0";"nM";"4.39";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.164 None | IC50 CI (lower) = 38.75 uM | IC50 CI (upper) = 42.08 uM | Maximum measured = 95.46 None | Maximum response = 100.0 % | Minimum measured = -2.966 None | R squared = 0.994 None";"";"";"40.376"
"CHEMBL5605673";"";"None";"425.90";"0";"4.15";"ASAP-0027729";"CCc1cc(C(=O)Nc2cccc(-n3nn[nH]c3=O)c2)sc1-c1ccc(Cl)cc1";"IC50";"'='";"11902.0";"nM";"4.92";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.214 None | IC50 CI (lower) = 11.07 uM | IC50 CI (upper) = 12.79 uM | Maximum measured = 91.3 None | Maximum response = 100.0 % | Minimum measured = -1.304 None | R squared = 0.991 None";"";"";"11.902"
"CHEMBL5605183";"";"None";"389.38";"0";"2.84";"ASAP-0030767";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'='";"93692.0";"nM";"4.03";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.938 None | IC50 CI (lower) = 84.52 uM | IC50 CI (upper) = 103.86 uM | Maximum measured = 50.37 None | Maximum response = 100.0 % | Minimum measured = -3.202 None | R squared = 0.987 None";"";"";"93.692"
"CHEMBL5605255";"";"None";"423.95";"0";"4.61";"ASAP-0030850";"C=CC[C@H]1NCc2cc(N[C@H](C(=O)NC(C)C)c3cc(Cl)cc4[nH]ncc34)ccc21";"IC50";"'='";"55092.0";"nM";"4.26";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.984 None | IC50 CI (lower) = 50.24 uM | IC50 CI (upper) = 60.41 uM | Maximum measured = 62.19 None | Maximum response = 100.0 % | Minimum measured = -3.679 None | R squared = 0.987 None";"";"";"55.092"
"CHEMBL5598684";"";"None";"433.31";"0";"4.85";"ASAP-0029352";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]c(-c3ccccc3)nc12";"IC50";"'='";"1475.0";"nM";"5.83";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.012 None | IC50 CI (lower) = 1.39 uM | IC50 CI (upper) = 1.565 uM | Maximum measured = 98.43 None | Maximum response = 100.0 % | Minimum measured = -0.564 None | R squared = 0.993 None";"";"";"1.475"
"CHEMBL5598860";"";"None";"325.41";"0";"3.36";"ASAP-0029521";"Cc1c(C(=O)Nc2cc([C@H]3CCOC3)ccn2)cc(C2CC2)n1C";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.102 None | Maximum measured = 36.69 None | Maximum response = 100.0 % | Minimum measured = -4.398 None | R squared = 0.953 None";"";"";"99.5"
"CHEMBL5598765";"";"None";"420.90";"0";"3.59";"ASAP-0029650";"Cn1cc(CCc2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(Cl)cc3[nH]2)cn1";"IC50";"'='";"23708.0";"nM";"4.62";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.185 None | IC50 CI (lower) = 19.22 uM | IC50 CI (upper) = 29.24 uM | Maximum measured = 76.31 None | Maximum response = 100.0 % | Minimum measured = -5.449 None | R squared = 0.941 None";"";"";"23.708"
"CHEMBL5598611";"";"None";"326.79";"0";"3.08";"ASAP-0029588";"Cn1cc2cc(Cl)cc(C(=O)Nc3ccc4c(c3)CNC4)c2n1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 6.988 None | Minimum measured = -51.45 None";"";"";"99.5"
"CHEMBL5606033";"";"None";"293.33";"0";"2.04";"ASAP-0029950";"O=C1Cc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc2N1";"IC50";"'='";"5441.0";"nM";"5.26";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.388 None | IC50 CI (lower) = 4.979 uM | IC50 CI (upper) = 5.945 uM | Maximum measured = 99.31 None | Maximum response = 100.0 % | Minimum measured = -5.492 None | R squared = 0.994 None";"";"";"5.441"
"CHEMBL5606232";"";"None";"278.31";"0";"2.42";"ASAP-0030093";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2cn[nH]c12";"IC50";"'='";"37269.0";"nM";"4.43";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.0 None | IC50 CI (lower) = 34.01 uM | IC50 CI (upper) = 40.84 uM | Maximum measured = 85.77 None | Maximum response = 100.0 % | Minimum measured = -4.233 None | R squared = 0.98 None";"";"";"37.269"
"CHEMBL5605022";"";"None";"321.32";"0";"2.43";"ASAP-0031265";"N#Cc1cc2c(cc1NC(=O)c1cc(F)cc3[nH]ncc13)CNC2";"IC50";"'='";"5390.0";"nM";"5.27";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.115 None | IC50 CI (lower) = 4.869 uM | IC50 CI (upper) = 5.967 uM | Maximum measured = 94.98 None | Maximum response = 100.0 % | Minimum measured = -6.366 None | R squared = 0.992 None";"";"";"5.39"
"CHEMBL5606319";"";"None";"426.47";"0";"2.76";"ASAP-0031155";"O=C(Nc1cc2c(c(C3=CCS(=O)(=O)CC3)c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'='";"12762.0";"nM";"4.89";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.126 None | IC50 CI (lower) = 11.47 uM | IC50 CI (upper) = 14.2 uM | Maximum measured = 89.3 None | Maximum response = 100.0 % | Minimum measured = -5.994 None | R squared = 0.989 None";"";"";"12.762"
"CHEMBL5605372";"";"None";"323.42";"0";"3.22";"ASAP-0031633";"NCc1csc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc12";"IC50";"'='";"9070.0";"nM";"5.04";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604073";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 3 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 3 (strain Philippines/H87/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 3";"None";"None";"None";"None";"Construct protein sequence: SMADLTVEKAADVTWEEEAEQTGVSHNLMITVDDDGTMRIKDDETENILGGGGSGGGGSGVLWDVPSPPETQKAELEEGVYRIKQQGIFGKTQVGVGVQKEGVFHTMWHVTRGAVLTHNGKRLEPNWASVKKDLISYGGGWRLSAQWQKGEEVQVIAVEPGKNPKNFQTMPGIFQTTTGEIGAIALDFKPGTSGSPIINREGKVVGLYGNGVVTKNGGYVSGIAQTNAEPDGPTPELEEEFRK";"";"";"CHEMBL5705863";"NS3 protease";"dengue virus type 3";"SINGLE PROTEIN";"CHEMBL5604065";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.601 None | IC50 CI (lower) = 8.634 uM | IC50 CI (upper) = 9.527 uM | Maximum measured = 99.27 None | Maximum response = 100.0 % | Minimum measured = -1.703 None | R squared = 0.996 None";"";"";"9.07"
